New Anxiety Medications for 2026 in the Pipeline

MM120 is an investigational treatment being developed by MindMed for generalized anxiety disorder (GAD). It uses a small, precisely controlled dose of a psychedelic compound (a form of LSD) that dissolves on the tongue.

In a Phase 2 study, participants reported improvement in anxiety symptoms after a single dose, with potential benefits observed for up to 12 weeks.

MM120 is now in Phase 3 of clinical trials, which are evaluating its effectiveness and safety. These studies are measuring changes in anxiety symptoms over 12 weeks and following participants for up to one year to assess long-term outcomes.

If successful, MM120 may become the first psychedelic-derived treatment the FDA has approved for GAD, offering a potentially fast-acting and long-lasting option for individuals who have not had success with existing treatments.

Glyph Allopregnanolone (GlyphAllo) is being developed by Seaport Therapeutics to treat major depressive disorder (MDD), including depression that occurs with significant anxiety symptoms.

Allopregnanolone is a naturally occurring substance that helps the brain use gamma-aminobutyric acid (GABA), the most abundant inhibitory neurotransmitter in the brain, that seems to help reduce stress and regulate mood. Historically, allopregnanolone has only been available as an intravenous (IV) injection because the body does not absorb it well when taken orally.

GlyphAllo is designed to improve oral absorption so that more of the medication reaches the brain. It remains in clinical trials, and researchers are studying whether GlyphAllo may provide a new treatment option for depression with anxious distress.

Fasedienol is a nasal spray being developed by Vistagen for social anxiety disorder. It uses a type of medicine called a pherine, which acts through nerves in the nasal passages that send signals directly to brain regions involved in mood, stress, and social comfort.

Because Fasedienol works locally in the nose rather than circulating throughout the body, it’s being studied for its potential to reduce anxiety quickly with fewer systemic effects. Researchers are exploring whether it can be used “as needed” before anxiety-provoking social situations.

If ongoing studies continue to show positive results, pherine nasal sprays like Fasedienol may become a new type of fast-acting, on-demand anxiety treatment.

Current medication treatments for anxiety disorders have long relied on Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), and benzodiazepines. The investigational medications now in development represent a shift toward new biological targets, precision delivery systems, and treatment approaches that go beyond traditional antidepressant mechanisms.

If upcoming trial results are positive, 2026 may mark a meaningful turning point, moving anxiety treatment toward faster-acting, more personalized, and more diverse therapeutic options.

This content includes forward-looking statements regarding investigational treatments that are not yet approved by the FDA and anticipated clinical milestones. These statements are based on publicly available information from third-party sources and are subject to change. Actual outcomes may differ materially from those expressed or implied. LifeStance does not guarantee approval, availability, or effectiveness of any investigational medication.